Oxaliplatin and infusional fluorouracil/leucovorin or capecitabine has emerged as important options in the adjuvant and palliative treatment of colorectal cancer. Severe Oxaliplatin induced neurotoxicity may require c...Oxaliplatin and infusional fluorouracil/leucovorin or capecitabine has emerged as important options in the adjuvant and palliative treatment of colorectal cancer. Severe Oxaliplatin induced neurotoxicity may require chemotherapy dose reduction or cessation. The incidence of oxaliplatin-induced neurotoxicity has varied from 12% - 18%. Several attempts have been proposed to prevent or treat oxaliplatin-induced neurotoxicity, but treatment of established chronic Oxaliplatin induced neurotoxicity is limited. Purpose: To assess the efficacy of parenteral Glutamine dipeptide (N2-L-Alanyl-L-Glutamine Dipeptide, 20 g·m/100ml, IV) for preventing of oxaliplatin induced neurotoxicity. Patients and Methods: A pilot study was performed. 120 patients with metastatic colorectal cancer (mCRC) entered into the study. 60 patients randomly assigned to receive IV glutamine dipeptide (20 g·m IV) day 1-2 with FOLFOX-4 to be repeated every 15 days as a first line of treatment of metastatic colorectal cancer and 60 patients assigned to receive only FOLFOX-4 (control group). Neurotoxicity symptoms and signs were evaluated before each cycle. Results: There were significantly fewer neurological symptoms in patients receiving glutamine dipeptide than in those who did not. A decreased percentage of grade 1-2 peripheral neuropathy was observed in the glutamine dipeptide group after two cycles (8.3% versus 20%;P = 0.04) and 4 cycles (13.3% vs 26.7%;P = 0.02). A significantly lower incidence of grade 3-4 neuropathy was noted in the glutamine dipeptide group after four and six cycles (6.7% versus 15%, P = 0.02 and 13.3% versus 33.3%. P = 0.04, respectively). The need for oxaliplatin dose reduction was significantly lower in the glutamine dipeptide (Dipeptiven) group (10% vs 26.7%;P = 0.02) and there were no significant differences between two groups in response to chemotherapy among patient with mCRC (48.3% vs 50%). Conclusion: These data concluded that IV dipeptide glutamine significantly decreases the incidence and severity of oxaliplatin in展开更多
A convenient and efficient synthesis of alanylglutaminewas was proposed.The procedure contained only two steps.It is more cost effective.Furthermore,the by product is very little.It was concluded that this method is e...A convenient and efficient synthesis of alanylglutaminewas was proposed.The procedure contained only two steps.It is more cost effective.Furthermore,the by product is very little.It was concluded that this method is economical and applicable to the synthesis of alanylglutamine(Ala Gln).展开更多
目的:探讨基于L-丙氨酰谷氨酰胺的肠外营养在重症监护病房(Intensive Care Unit,ICU)重症颅脑损伤的应用价值.方法:2018年6月到2020年6月选择在本院ICU诊治的重症颅脑损伤患者540例,根据随机数字表法把患者分为研究组与对照组各270例....目的:探讨基于L-丙氨酰谷氨酰胺的肠外营养在重症监护病房(Intensive Care Unit,ICU)重症颅脑损伤的应用价值.方法:2018年6月到2020年6月选择在本院ICU诊治的重症颅脑损伤患者540例,根据随机数字表法把患者分为研究组与对照组各270例.对照组给予标准肠外营养支持方法,研究组在对照组治疗的基础上给予L-丙氨酰谷氨酰胺辅助治疗,两组都治疗观察14d.结果:研究组治疗第7d与14d的营养不足发生率分别为4.8%和6.7%,显著低于对照组的13.0%和17.0%(P<0.05).两组治疗后的血清总蛋白与白蛋白含量高于治疗前,研究组高于对照组,对比差异都有统计学意义(P<0.05).研究组治疗期间的肺部感染、尿路感染、消化道反应、压疮等并发症发生率为4.8%,显著低于对照组的15.6%(P<0.05).两组治疗后的血清降钙素原(Procalcitonin,PCT)值低于治疗前,研究组低于对照组,对比差异都有统计学意义(P<0.05).结论:基于L-丙氨酰谷氨酰胺的肠外营养在ICU重症颅脑损伤的应用能降低患者营养不足与并发症发生率,促进恢复机体的营养状况,抑制PCT的释放.展开更多
文摘Oxaliplatin and infusional fluorouracil/leucovorin or capecitabine has emerged as important options in the adjuvant and palliative treatment of colorectal cancer. Severe Oxaliplatin induced neurotoxicity may require chemotherapy dose reduction or cessation. The incidence of oxaliplatin-induced neurotoxicity has varied from 12% - 18%. Several attempts have been proposed to prevent or treat oxaliplatin-induced neurotoxicity, but treatment of established chronic Oxaliplatin induced neurotoxicity is limited. Purpose: To assess the efficacy of parenteral Glutamine dipeptide (N2-L-Alanyl-L-Glutamine Dipeptide, 20 g·m/100ml, IV) for preventing of oxaliplatin induced neurotoxicity. Patients and Methods: A pilot study was performed. 120 patients with metastatic colorectal cancer (mCRC) entered into the study. 60 patients randomly assigned to receive IV glutamine dipeptide (20 g·m IV) day 1-2 with FOLFOX-4 to be repeated every 15 days as a first line of treatment of metastatic colorectal cancer and 60 patients assigned to receive only FOLFOX-4 (control group). Neurotoxicity symptoms and signs were evaluated before each cycle. Results: There were significantly fewer neurological symptoms in patients receiving glutamine dipeptide than in those who did not. A decreased percentage of grade 1-2 peripheral neuropathy was observed in the glutamine dipeptide group after two cycles (8.3% versus 20%;P = 0.04) and 4 cycles (13.3% vs 26.7%;P = 0.02). A significantly lower incidence of grade 3-4 neuropathy was noted in the glutamine dipeptide group after four and six cycles (6.7% versus 15%, P = 0.02 and 13.3% versus 33.3%. P = 0.04, respectively). The need for oxaliplatin dose reduction was significantly lower in the glutamine dipeptide (Dipeptiven) group (10% vs 26.7%;P = 0.02) and there were no significant differences between two groups in response to chemotherapy among patient with mCRC (48.3% vs 50%). Conclusion: These data concluded that IV dipeptide glutamine significantly decreases the incidence and severity of oxaliplatin in
文摘A convenient and efficient synthesis of alanylglutaminewas was proposed.The procedure contained only two steps.It is more cost effective.Furthermore,the by product is very little.It was concluded that this method is economical and applicable to the synthesis of alanylglutamine(Ala Gln).
文摘目的:探讨基于L-丙氨酰谷氨酰胺的肠外营养在重症监护病房(Intensive Care Unit,ICU)重症颅脑损伤的应用价值.方法:2018年6月到2020年6月选择在本院ICU诊治的重症颅脑损伤患者540例,根据随机数字表法把患者分为研究组与对照组各270例.对照组给予标准肠外营养支持方法,研究组在对照组治疗的基础上给予L-丙氨酰谷氨酰胺辅助治疗,两组都治疗观察14d.结果:研究组治疗第7d与14d的营养不足发生率分别为4.8%和6.7%,显著低于对照组的13.0%和17.0%(P<0.05).两组治疗后的血清总蛋白与白蛋白含量高于治疗前,研究组高于对照组,对比差异都有统计学意义(P<0.05).研究组治疗期间的肺部感染、尿路感染、消化道反应、压疮等并发症发生率为4.8%,显著低于对照组的15.6%(P<0.05).两组治疗后的血清降钙素原(Procalcitonin,PCT)值低于治疗前,研究组低于对照组,对比差异都有统计学意义(P<0.05).结论:基于L-丙氨酰谷氨酰胺的肠外营养在ICU重症颅脑损伤的应用能降低患者营养不足与并发症发生率,促进恢复机体的营养状况,抑制PCT的释放.
